Latham & Watkins LLP represented Arcutis Biotherapeutics, Inc. in the transaction. Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) has announced the pricing of its upsized underwritten public offering…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
